CLLS

TentativeAI Memo

Cellectis

As of 2026-10-20/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

low

Horizon

—

Key catalyst

.HEAL-101 preliminary Phase 1 data • 2027-12-31

Base target: $1 / p=50% prob

Biggest risk

The company exited the clinical-stage CAR-T programs that had anchored its earlier investment case. Replacement programs remain preclinical, their first planned data are distant, and cost savings have not yet been demonstrated in reported cash trends.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The strategic reset concentrates resources on two in vivo programs, while management targets runway into H2 2028. Credible first-in-human .HEAL-101 data could restore confidence in the platform. [#IR-2026-09-14] https://www.cellectis.com/en/press/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company/

Research note

Recommendation

—

Confidence

low

As of

2026-10-20

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Cost realignment and runway execution
.HEAL-201 preliminary Phase 1 data
The strategic reset concentrates resources on two in vivo programs, while management targets runway into H2 2028.

BearKey bullets

China investigator-initiated trial timing, enrollment and the applicability of its data to later regulatory development remain uncertain.
No dependable post-reset analyst estimate or target revisions are available in the packet.
Preclinical efficacy may not translate into safe, durable human benefit for either in vivo program.

WatchKey bullets

.HEAL-101 preliminary Phase 1 data

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=50%)

Target spread vs base: +88% / -53%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=50%)Bear Target: $0 (p=30%)

Commentary

The September strategic reset dominates the available headlines. The $0.9255 October 19 anchor is about 39% below the $1.51 September 21 price recorded in the prior baseline, but that comparison does not isolate a single news event. Social, options, short-interest and employee metrics are unavailable; zero values above denote unavailable data, not neutral readings. The deterministic prior is negative, with low evidence quality (0.08) and high uncertainty (0.931).

As of 2026-10-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Cost realignment and runway execution
.HEAL-201 preliminary Phase 1 data

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-10-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.70

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-12-31
.HEAL-101 preliminary Phase 1 data
Cellectis plans a China investigator-initiated Phase 1 trial of its APOC3 base-editing candidate and preliminary clinical data in H2 2027. Human safety and triglyceride-lowering results would test a thesis currently supported by preclinical data. [#IR-2026-09-14] https://www.cellectis.com/en/press/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company/
Prob 55.00% • Move 45.00% • Priced-in 15.00%

Short-term Catalysts

Next few weeks

Cost realignment and runway execution
2027-03-31
After ending internal development of lasme-cel and eti-cel, Cellectis aims to extend its cash runway into H2 2028 through operating realignment. The next meaningful test is whether spending and cash disclosures substantiate that plan; no completion date for the realignment was provided. [#IR-2026-09-14] https://www.cellectis.com/en/press/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company/
Prob 65% • Move 10% • Priced-in 40%

Long-term Catalysts

Months to a year

.HEAL-201 preliminary Phase 1 data
2028-06-30
Cellectis plans a China investigator-initiated Phase 1 trial of its PCSK9 epigenetic-editing candidate and preliminary data in H1 2028. Translating preclinical PCSK9 suppression into durable human benefit remains unproven. [#IR-2026-09-14] https://www.cellectis.com/en/press/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company/
Prob 45% • Move 40% • Priced-in 10%

Risks

China investigator-initiated trial timing, enrollment and the applicability of its data to later regulatory development remain uncertain.
No dependable post-reset analyst estimate or target revisions are available in the packet.
Preclinical efficacy may not translate into safe, durable human benefit for either in vivo program.
Realignment may not deliver the targeted H2 2028 runway; the estimate excludes proceeds from potential partnering of the discontinued CAR-T programs. [#IR-2026-09-14]

Peers

Symbol	Summary
ARCT	A loose LNP-delivery and clinical-translation comparator from the prior baseline. Different therapeutic modality and pipeline maturity limit valuation read-through.
BEAM	A modality comparator for liver-directed, LNP-delivered base editing, but its clinical-stage programs are more advanced and target different diseases; it is not a direct valuation multiple. https://beamtx.com/pipeline/

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-20

Loading AI feed…

Symbol

Summary

ARCT

A loose LNP-delivery and clinical-translation comparator from the prior baseline. Different therapeutic modality and pipeline maturity limit valuation read-through.

BEAM

A modality comparator for liver-directed, LNP-delivered base editing, but its clinical-stage programs are more advanced and target different diseases; it is not a direct valuation multiple. https://beamtx.com/pipeline/